Loading organizations...
§ Private Profile · Amsterdam, The Netherlands
Regenesance BV is a company.
Key people at Regenesance BV.
Regenesance BV develops novel pharmaceutical products focused on addressing immune-mediated disorders and accelerating nerve regeneration. The company designs therapies targeting critical pathways to restore neurological function and mitigate disease progression. Their scientific approach emphasizes innovative solutions for complex medical challenges, particularly in areas of unmet patient need.
Founded in November 2009, Regenesance BV emerged from groundbreaking research at the Academic Medical Center (AMC). Co-founders Dr. Kees Fluiter and Dr. Valeria Ramaglia, both research scientists from the Neurogenetics Laboratory, leveraged their deep understanding of neurobiology and immunology. Their initial insights into nerve damage and immune dysfunction formed the basis for the company's therapeutic development.
Regenesance BV’s pipeline targets patients suffering from severe immune-mediated conditions and various neurological disorders, including orphan indications. The company’s vision is to advance clinical development to offer significant improvements in patient outcomes. They aim to translate scientific discovery into impactful treatments that enhance quality of life for individuals with debilitating conditions.
Regenesance BV is a Netherlands‑based biotech spin‑out from the Academic Medical Center (AMC) in Amsterdam that develops complement‑inhibiting therapeutics to slow or prevent neurodegeneration, and later rebranded/merged into what is today known as Complement Pharma (formerly Regenesance). [1][2]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech/Healthcare Landscape
Quick Take & Future Outlook
Limitations and notes
Key people at Regenesance BV.